BCG vaccination and its possible effects on the acceleration of incidence and mortality by the new coronavirus: first step
DOI:
https://doi.org/10.1590/SciELOPreprints.117Keywords:
COVID-19, Coronavirus, BCG vaccine, Incidence, LethalityAbstract
Introduction: BCG vaccine (bacillus Calmette–Guérin) has been developed against tuberculosis and proven to be used for other purposes by activating and/or training innate immunity. The protective effect against the new coronavirus should be investigated and tested while a specific vaccine is not available. Objective: To compare the acceleration rates of incidence and lethality of COVID-19 according to the vaccination program for BCG of the main countries affected by the pandemic. Methods: Part one of three of the data survey from official sources on the number of cases and number of deaths by COVID-19 between December 31, 2019 and April 11, 2020, being calculated the incidence, mortality and lethality acceleration rates, and compared among predefined groups according to their BCG vaccination programs. Results: Countries without a vaccination program in place or that never had one for BCG had incidence and mortality acceleration rates of 21.36 and 53.21 times higher (p < 0.001), respectively, than the same rates in countries with a universal vaccination program. In addition, patients with an expanded vaccination program had a 43% lower mortality rate (p < 0.001) compared to countries with a vaccination program at birth only. Conclusion: There is a correlation between the coverage of BCG vaccination programs and the acceleration in the number of new cases and deaths in countries, showing a possible protective factor in places with existing BCG vaccination programs.
Downloads
Metrics
Posted
How to Cite
Section
Copyright (c) 2020 Carlos Eduardo Duarte, Guilherme Gaeski Passuello, Raquel Almeida Lopes Neves, Fernanda Cappi Santos Duarte

This work is licensed under a Creative Commons Attribution 4.0 International License.